Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Apalutamide With or Without Abiraterone Acetate and GnRH Agonist in High-Risk Prostate Cancer
NCT02949284Phase 2Active, not recruiting
- Sponsor
- Rutgers University
- Start
- Jun 2017
- Primary completion
- Sep 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of apalutamide in prostate cancer (PCa) (3 arms), sponsored by Rutgers University. Primary endpoint: Post-surgical potency rate defined as successful intercourse in half the attempts at 12 months. Started Jun 2017; status: active, not recruiting.
02
Drugs
apalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02949284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02949284.